---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-24-000038"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:39:42.177271+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nautilus Q1 net loss $18.7M vs $15.0M YoY; cash $247.7M

## Summary
- Net loss of $18.7M widened from $15.0M in Q1 2023; no revenue reported.
- Operating expenses $21.6M, up 20% YoY on higher headcount for platform development.
- Cash, equivalents and investments $247.7M as of March 31, 2024.
- CEO cites progress on consumables, assay, instrument and software scale/reproducibility.

## SEC filing metadata
- accession: 0001808805-24-000038
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000038/0001808805-24-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000038/naut-20240430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-24-000038
- JSON: https://secwatch.observer/filing/0001808805-24-000038.json
- Plain text: https://secwatch.observer/filing/0001808805-24-000038.txt

## Key facts
- Earnings Releases
  Nautilus Biotechnology, Inc. reported the first quarter ended March 31, 2024 results: net income $18.7 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: $18.7 million
  - Result: reported results
  source text: Net loss was $18.7 million for the first quarter of 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000038/0001808805-24-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.